The in Vitro Activity of Tigecycline Against the Multidrug Resistant Acinetobacter Spp. at a Tertiary Care Hospital

DIPENDER KAUR NAJOTRA, POONAM SLATHIA, NIRAJ KUMAR, SANJEEV KUMAR DIGRA

ABSTRACT
Background: The Acinetobacter spp., particularly A. baumannii, has emerged as one of the most troublesome pathogens in healthcare institutions globally, because they are often Multi Drug Resistant (MDR), which means that the therapy and the infection control are complicated. With the emergence of the carbapenemase-producing isolates which show resistance to all the available agents except the polymyxins, this genus deserves close attention. In this scenario, tigecycline, a glycyclcline which has a spectrum of activity which is unparalleled by any other broad spectrum agent, and is not affected by most of the known mechanisms of resistance to tetracycline which have been encountered in bacteria, is a useful alternative for the treatment of the infections which are caused by the Acinetobacter spp.

Aim: This study was conducted to investigate the in vitro activity of tigecycline against a collection of MDR isolates of Acinetobacter spp. from our hospital.

Material and Methods: A prospective, hospital based study was conducted from October 2010 to April 2012 in which all the Acinetobacter spp. isolates which were obtained from clinical samples, were subjected to the testing of their antimicrobial susceptibilities to different groups of drugs, which included tigecycline. Based on the susceptibility profile, the isolates which were labeled as MDR were further subjected to the Epsilometer test (E-test) to determine the minimum inhibitory concentrations (MIC) of tigecycline.

Results: A total of 85 Acinetobacter spp. isolates were obtained, out of which 38 (44.7%) were labeled as MDR. 91.8% of the total and 81.5% of the MDR isolates were sensitive to tigecycline and the MICs of tigecycline for these MDR isolates ranged from 0.25 to 32 μg/ml.

Conclusion: This study proved that tigecycline exhibited a good in vitro activity against the clinical isolates of the MDR Acinetobacter spp., and that it may be considered as a promising therapeutic option for the treatment of the nosocomial infections which were caused by these pathogens. But the tigecycline resistance among the isolates that had not previously been exposed to the drug is worrisome. So before starting the treatment, the in vitro susceptibility of the isolates to tigecycline and its MIC should be assessed.

Key Words: Acinetobacter spp., Tigecycline, MDR, MIC, E-test

INTRODUCTION
The Acinetobacter spp., particularly A. baumannii, has emerged as one of the most troublesome pathogens for the healthcare institutions globally. Hospital acquired pneumonia is still the most common infection which is caused by this organism. However, in the more recent times, the infections which involve the central nervous system, skin and soft tissue, and the bone have emerged as highly problematic for certain institutions [1,2].

The mortality which is due to the nosocomial infections which are caused by A. baumannii is high, reaching from 25 to 34% for bacteremia and from 40 to 80% for nosocomial pneumonia [3,4]. This genus deserves close attention as it displays mechanisms of resistance to all the existing antibiotic classes, as well as a prodigious capacity to acquire new determinants of resistance [5].

Many carbapenemase-producing A. baumannii isolates are resistant to all the available therapeutic agents except the polymyxins and to the drugs with significant toxicity and poor penetration to respiratory secretions [6].

Acting in synergy with this emerging resistance profile is the un-canny ability of Acinetobacter spp. to survive for prolonged periods throughout the hospital environment, thus potentiating its ability for nosocomial spreads [2]. In this scenario, tigecycline, a 9-t-butylglyclamide derivative of minocycline, which has a spectrum of activity which is unparalleled by any other broad spectrum agent, and is not affected by most of the known mechanisms of resistance to tetracycline (ribosomal protection and active drug efflux) which have been encountered in bacteria, is a useful alternative to the polymyxins [6].

Tigecycline acts by the inhibition of the protein translation in bacteria, by binding to the 30S ribosomal subunit, and by blocking the entry of the amino-acyl tRNA molecules into the A site of the ribosome [7].

But in view of the increasing number of reports of the variable susceptibility of tigecycline against the Multiple Drug Resistant (MDR) Acinetobacter spp. isolates around the world and the few therapeutic options which are available for the treatment of the infections which are caused by this organism, this study was conducted to investigate the in vitro activity of tigecycline against a collection of MDR isolates of Acinetobacter spp. at our hospital.
MATERIALS AND METHODS

A prospective study was conducted at the Acharya Shri Chander College of Medical Sciences and Hospital, Jammu, India, from October 2010 to April 2012. All the MDR Acinetobacter spp. isolates which were obtained from the clinical samples which were received in the microbiology laboratory of our hospital were included in this study. None of the patients had undergone any previous treatment with tigecycline and only one isolate per patient was included in the study. The isolates were identified by the standard laboratory methods [8]. The testing of the antimicrobial susceptibility of the isolated strains to the different groups of drugs was carried out on Mueller-Hinton agar by the Kirby Bauer disc diffusion method, and the results were interpreted as was recommended by the CLSI (Clinical Laboratory Standards Institute) guidelines [9].

The interpretation of the zone diameters of tigecycline was done by using the US FDA susceptible breakpoints [10]. Pseudomonas aeruginosa ATCC 27853 was used as a quality control. The following antimicrobial agents (μg) were used - cefotaxime (30), cefepime(30), ceftazidime (30) gentamicin (10), amikacin (30), ciprofloxacin (5), levofloxacin (10), co-trimoxazole (1/2:23.8), imipenem (10), piperacillin and tazobactam (75+10), cefoperazone and sulbactam (75+30), tigecycline (15), colistin (10) and nitrofurantoin (30), which was tested only for the urinary isolates.

The MDR phenotype was defined as the resistance to more than two of the following five drug classes: antipseudomonal cephalosporins, antipseudomonal carbapenems, β-lactam/β-lactamase inhibitor combinations, fluoroquinolones and aminoglycosides. The isolates which were resistant to all the drug classes which included the glycylcyclines and the polymixins were further labelled as pan drug resistant (PDR) [2].

Minimum inhibitory concentration testing (MIC):

The MIC of tigecycline was determined for all the MDR Acinetobacter spp. isolates by using the E-test strips according to the manufacturer’s instructions. The MIC breakpoints which were used were ≤2 μg/ml also had a zone diameter of ≥19 mm (the cut-off for the susceptibility). Similarly, the three isolates which had an MIC of ≤2 μg/ml also had a zone diameter of ≥19 mm (the cut-off for the susceptibility). The most significant finding was the reporting of two (2.4% of the total) PDR Acinetobacter spp. isolates which were resistant to both tigecycline and colistin. These PDR isolates were also resistant to imipenem. On being considered alone, 91.8% of the total isolates and 81.5% of the MDR isolates were found to be sensitive to tigecycline.

The MICs of tigecycline were determined for all the MDR Acinetobacter spp. isolates by using the E-test strips according to the manufacturer’s instructions. The MIC breakpoints which were used were ≤2 μg/ml also had a zone diameter of ≥19 mm (the cut-off for the susceptibility).

TABLE/Figure-1: Antimicrobial susceptibility pattern of Acinetobacter spp. isolates (n=85)

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>No. of sensitive isolates (%)</th>
<th>No. of resistant isolates (%)</th>
<th>No. of intermediate sensitive isolates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefotaxime</td>
<td>19(22.4)</td>
<td>62(72.9)</td>
<td>4(4.7)</td>
</tr>
<tr>
<td>Cefepime</td>
<td>15(17.6)</td>
<td>65(76.5)</td>
<td>5(5.9)</td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>21(24.7)</td>
<td>63(74.1)</td>
<td>1(1.2)</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>20(23.5)</td>
<td>63(74.1)</td>
<td>2(2.4)</td>
</tr>
<tr>
<td>Amikacin</td>
<td>21(24.7)</td>
<td>61(71.8)</td>
<td>3(3.5)</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>24(28.2)</td>
<td>60(70.6)</td>
<td>1(1.2)</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>25(29.4)</td>
<td>58(68.2)</td>
<td>2(2.4)</td>
</tr>
<tr>
<td>Cotrimoxazole</td>
<td>12(14.1)</td>
<td>72(84.7)</td>
<td>1(1.2)</td>
</tr>
<tr>
<td>Imipenem</td>
<td>67(78.8)</td>
<td>15(17.6)</td>
<td>3(3.5)</td>
</tr>
<tr>
<td>Piperacillin/tazobactum</td>
<td>61(71.8)</td>
<td>18(21.2)</td>
<td>6(7)</td>
</tr>
<tr>
<td>Cefoperazone/sulbactum</td>
<td>63(74.1)</td>
<td>17(20)</td>
<td>5(5.9)</td>
</tr>
<tr>
<td>Tigecycline</td>
<td>78(91.8)</td>
<td>4(4.7)</td>
<td>3(3.5)</td>
</tr>
<tr>
<td>Colistin</td>
<td>83(97.6)</td>
<td>2(2.4)</td>
<td>Nil</td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td>1(11.1)</td>
<td>77(87.8)</td>
<td>1(11.1)</td>
</tr>
</tbody>
</table>

TABLE/Figure-2: Age distribution of the Acinetobacter spp. isolates

<table>
<thead>
<tr>
<th>Age in years</th>
<th>Acinetobacter spp.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of isolates</td>
</tr>
<tr>
<td>0-5</td>
<td>12</td>
</tr>
<tr>
<td>5-20</td>
<td>9</td>
</tr>
<tr>
<td>20-40</td>
<td>13</td>
</tr>
<tr>
<td>40-60</td>
<td>34</td>
</tr>
<tr>
<td>60-80</td>
<td>17</td>
</tr>
</tbody>
</table>

TABLE/Figure-3: MIC of tigecycline for MDR Acinetobacter spp. isolates (n=38)

<table>
<thead>
<tr>
<th>MIC of tigecycline (μg/ml)</th>
<th>No. of isolates</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.25</td>
<td>11</td>
</tr>
<tr>
<td>0.5</td>
<td>12</td>
</tr>
<tr>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>16</td>
<td>1</td>
</tr>
<tr>
<td>32</td>
<td>1</td>
</tr>
</tbody>
</table>
an MIC of 4 μg/ml were found to be intermediate (15-18mm) and the isolates with an MIC of ≥8 μg/ml were found to be resistant (≤14mm) by the disc diffusion method.

**DISCUSSION**

In the present study, the predominant source of the Acinetobacter spp. isolates was the respiratory tract, which is consistent with the findings of various other studies which were done in different parts of the world [12-14]. The prevalence rate of the multi drug resistance in the Acinetobacter spp. isolates was 44.7%, which is comparable to that which was reported by Taneja et al., [15], but it was quiet high as compared to that in a study which was done by Kuo et al., [16], who reported MDR rates of 21.4 and 8.9 per cent in catheterized patients and in respiratory samples respectively.

Further, various authors have reported the resistance rate to tigecycline to vary from being nonexistent to 66 % [13-15], [17-19]. But in the present study, tigecycline was shown to have a good sensitivity (81.5%) against the MDR Acinetobacter spp., which was almost comparable to that which was reported by Insa et al., [12].

In our study, the E test correlated 100 percent with the inhibition zone diameters, which was in contrast to the findings of a study which was done by Behera et al., [19] but it was similar to the findings of a study which was done by Venezia et al., [18].

Inspite of the high sensitivity rate, the finding of the increased tigecycline MIC values (8-32μg/ml) for four Acinetobacter spp. isolates in our study was a cause of concern, since this organism was not only totally unexposed to tigecycline but also to the tetra-cycline group of antibiotics in our hospital. It has been described that mutations of tet(A) selected in vitro could enable the efflux of glycolcyclines and that the up-regulation of the chromosomally-mediated efflux pumps could lead to the resistance of the Acinetobacter spp. to tigecycline [6,20].

In the present study, we reported 2.3% of the Acinetobacter spp. to be pan drug resistant, which although was lower as compared to the 3.5% which was reported by Taneja et al., [15], was significant, as it signified the beginning of the era where only a few therapeutic options would be available for their treatment.

**CONCLUSION**

The treatment options for the infections which are caused by multidrug resistant organisms are very limited, and tigecycline is rapidly finding a role in the treatment of severe infections, as this antimicrobial has a favourable in vitro activity against a wide variety of organisms, which include the MDR Acinetobacter spp. But the tigecycline resistance among the MDR isolates that had not previously been exposed to this drug and also the emergence of PDR isolates is worrisome.

So before starting the treatment, the in vitro susceptibility to tigecycline should be assessed, to prevent the development and the dissemination of resistance against this one of the last available promising and safe therapeutic options which is available to the clinicians for combating these bacteria.

**REFERENCES**

AUTHOR(S):
1. Dr. Dipender Kaur Najotra
2. Dr. Poonam Slathia
3. Dr. Niraj Kumar
4. Dr. Sanjeev Kumar Digra

PARTICULARS OF CONTRIBUTORS:
1. Senior Resident, Department of Microbiology,
   Acharya Shri Chander College of Medical Sciences and Hospital, Jammu, J&K, India.
2. Assistant Professor, Department of Paediatrics,
   Govt. Medical College, Jammu, J&K, India.
3. Senior Resident, Department of Paediatrics,
   Govt. Medical College, Jammu, J&K, India.
4. Assistant Professor, Department of Paediatrics,
   Govt. Medical College, Jammu, J&K, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:
Dr. Dipender Kaur Najotra,
Senior Resident, Department of Microbiology,
207-D uttam nagar Kunjwani Bye- pass, Jammu,
Jammu and Kashmir, Pin code- 180010, India.
Phone: 09419135664
E-mail: chahalovely@yahoo.co.in

FINANCIAL OR OTHER COMPETING INTERESTS:
None.

Date of Submission: Jun 30, 2012
Date of Peer Review: Jul 24, 2012
Date of Acceptance: Sep 11, 2012
Date of Publishing: Sep 30, 2012